NIH launches clinical trial where people who have had Pfizer or Johnson & Johnson will receive a third Moderna booster shot
- A study led by the NIH will test the effectiveness of mixing COVID-19 vaccines
- A total of 150 fully vaccinated participants who received Pfizer, Moderna, or Johnson & Johnson vaccines will all receive the Moderna booster shot
- Boosters may be needed to fight the many evolving variants of the virus, which are more contagious
- Researchers hope to determine which combination of the vaccines is most effective at combating variants
- The first results of the study are expected to be available in late summer 2021
The National Institutes of Health (NIH) has begun clinical trials investigating the effects of mixing different COVID-19 vaccines.
Currently, vaccine manufacturers are developing booster shots to protect against more contagious and contagious variants.
Adults will be enrolled who have been fully vaccinated with one of three vaccines approved for emergency use in the US: Pfizer-BioNTech, Moderna or Johnson & Johnson.
Some participants get a booster shot made by the same company that made their first doses, and others get the booster from a different company.
NIH researchers want to determine whether mixing vaccines is not only safe but also boosts immunity.
The NIH is conducting a study to see if different Covid-19 vaccines can be mixed. They will test the Moderna booster shot on participants who have received one of three available vaccines to find out which one is most effective at fighting viruses.
Dr. Fauci has said a third booster shot will be needed to protect Americans from virus variants. Early Pfizer Trials Show Americans May Need Their Third Injection As early as September
“While the vaccines currently approved by the U.S. Food and Drug Administration offer strong protection against COVID-19, we must prepare for the possibility that we will need booster shots to counteract waning immunity and keep pace. with an evolving virus,” said Dr. Anthony Fauci. , director of the National Institute of Allergy and Infectious Diseases, which is leading and funding the study.
“The results of this trial are intended to inform public health policy decisions about the potential use of mixed vaccine schedules when booster doses are indicated.”
The study, led by a Baylor College researcher, will include 150 Americans who have already been fully vaccinated.
Each member of the study, regardless of which of the vaccines they received, will receive a dose of Moderna booster injection designed to combat vaccine variants.
Participants who initially received the Moderna injection will also receive the Moderna booster to function as a control group.
Over the next year, data will be collected and participants will be evaluated to see how safe they are from the virus, as well as whether there are any unique side effects of mixing vaccines.
There will also be a separate group of unvaccinated individuals who will receive two doses of the Moderna vaccine for the study and then receive the third injection 12 to 20 weeks later.
Study members who become ill with the virus COVID-19 are tested for a variant and determined which vaccine combination is most effective against the many variants of the virus.
The first results of the study are expected by the end of the summer.
The study’s announcement comes as Americans may soon need another booster shot of the Covid-19 vaccine to stay protected from the virus.
Albert Bourla, CEO of Fauci and Pfizer, told Axios last month that a third dose of their vaccine will likely be necessary for Americans.
Early clinical trials show that the third dose may be needed as early as September for those who received the vaccine early.
The booster shots are likely needed due to the many variants of the virus circulating around the world, and many more are likely to emerge as the pandemic continues into other countries in 2021 and beyond.
Currently, more than 60 percent of American adults have received at least one dose of a Covid-19 vaccine, but there are reports of millions not showing up to get their second dose.